Tiziana Life Sciences Reports Interim Financials & Program Update
Ticker: TLSA · Form: 6-K · Filed: Oct 3, 2025 · CIK: 1723069
Sentiment: neutral
Topics: financials, corporate-update, biotech
Related Tickers: TLSA
TL;DR
Tiziana Life Sciences (TLSA) dropped its H1 2025 financials and program update. Check the details.
AI Summary
Tiziana Life Sciences Ltd. filed a Form 6-K on October 3, 2025, reporting its interim financial results for the six months ended June 30, 2025. The filing also provided a corporate update on its lead development programs.
Why It Matters
This filing provides investors with a mid-year financial snapshot and progress report on the company's key drug development initiatives.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical development stage, which inherently carries significant risks related to clinical trials, regulatory approval, and market adoption.
Key Players & Entities
- Tiziana Life Sciences Ltd (company) — Registrant
- June 30, 2025 (date) — End of interim reporting period
- October 3, 2025 (date) — Filing date
FAQ
What are Tiziana Life Sciences' lead programs mentioned in the update?
The filing states that a corporate update on its lead programs in development was provided, but the specific programs are not detailed within the provided text of the 6-K.
What period do the interim financial results cover?
The interim financial results cover the six months ended June 30, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Does Tiziana Life Sciences file annual reports under Form 20-F?
Yes, the company indicates it files annual reports under cover of Form 20-F.
When was Tiziana Life Sciences Ltd. formerly known as Tiziana Life Sciences plc?
The company was formerly known as Tiziana Life Sciences plc, with a date of name change on November 16, 2017.
Filing Stats: 343 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-10-03 16:30:01
Filing Documents
- ea0260194-6k_tiziana.htm (6-K) — 16KB
- ea026019401ex99-1_tiziana.htm (EX-99.1) — 457KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-1_002.jpg (GRAPHIC) — 42KB
- 0001213900-25-096118.txt ( ) — 538KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TIZIANA LIFE SCIENCES LTD Date: October 3, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 2 EXHIBIT INDEX Exhibit No. Description 99.1 Tiziana Life Sciences LTD Interim Results and Update, dated October 3, 2025 3